"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 25 | 31 | 56 |
| 2018 | 27 | 25 | 52 |
| 2019 | 11 | 11 | 22 |
| 2020 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study. Pharmacol Rep. 2021 Jun; 73(3):926-938.
-
A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients. Int J Tuberc Lung Dis. 2021 May 01; 25(5):409-412.
-
GeneXpert for the diagnosis of COVID-19 in LMICs. Lancet Glob Health. 2020 12; 8(12):e1457-e1458.
-
It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV. Am J Trop Med Hyg. 2020 10; 103(4):1348-1349.
-
Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. Int J Biol Macromol. 2020 Nov 15; 163:1787-1797.
-
Rifampicin-Induced Pneumonitis Mimicking Severe COVID-19 Pneumonia Infection. Am J Case Rep. 2020 Aug 25; 21:e927586.
-
Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazid. Clin Infect Dis. 2020 08 22; 71(5):1161-1167.
-
4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor. Int J Mol Sci. 2020 Aug 19; 21(17).
-
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. Trends Immunol. 2020 10; 41(10):856-859.
-
Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin. Pan Afr Med J. 2020; 35(Suppl 2):110.